Fibla Juan J, Brunelli Alessandro, Cassivi Stephen D, Deschamps Claude
Division of General Thoracic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Interact Cardiovasc Thorac Surg. 2012 Aug;15(2):276-9. doi: 10.1093/icvts/ivs174. Epub 2012 May 17.
In order to develop a practical risk score for 90-day mortality following surgical lung biopsy (SLB) for interstitial lung disease (ILD) we reviewed 311 consecutive patients undergoing SLB for ILD between 2002 and 2009. Postoperative complication, 30-day and 90-day mortality rates were 11.5%, 9% and 10.6% respectively. Univariable and multivariable analyses, validated by bootstrap statistics, were used to identify factors associated with 90-day mortality. A scoring system was developed by proportionally weighting the regression coefficients of the significant predictors of 90-day mortality: age >67 (P < 0.0001, weighted score 1.5), preoperative intensive care unit (ICU) admission (P = 0.006, weighted score 2), immunosuppressive treatment (P = 0.004, weighted score 1.5) and open surgery (P = 0.03, weighted score 1). Patients were grouped in four classes showing incremental risk of death at 90 days: class A, score 0 (2%); class B, score 1-2 (12%); class C, score 2.5-3 (40%); class D, score >3 (86%); P <0.0001). SLB entails a considerable surgical risk with an overall 90-day mortality around 10%. We were able to develop a practical risk score which, if validated by other independent studies, can be easily used to stratify the risk of SLB candidates and assess the cost-effectiveness of this procedure.
为了制定一个针对间质性肺疾病(ILD)患者进行外科肺活检(SLB)后90天死亡率的实用风险评分,我们回顾了2002年至2009年间连续接受SLB治疗的311例ILD患者。术后并发症、30天和90天死亡率分别为11.5%、9%和10.6%。采用单变量和多变量分析,并通过自抽样统计进行验证,以确定与90天死亡率相关的因素。通过按比例加权90天死亡率的显著预测因素的回归系数来制定评分系统:年龄>67岁(P<0.0001,加权分数1.5)、术前入住重症监护病房(ICU)(P = 0.006,加权分数2)、免疫抑制治疗(P = 0.004,加权分数1.5)和开放手术(P = 0.03,加权分数1)。患者被分为四类,显示出90天时死亡风险递增:A类,分数为0(2%);B类,分数为1 - 2(12%);C类,分数为2.5 - 3(40%);D类,分数>3(86%);P<0.0001)。SLB具有相当大的手术风险,总体90天死亡率约为10%。我们能够制定一个实用的风险评分,如果经其他独立研究验证,可轻松用于对SLB候选者的风险进行分层,并评估该手术的成本效益。